Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price hit a new 52-week low during trading on Thursday . The company traded as low as C$0.01 and last traded at C$0.02, with a volume of 31000 shares changing hands. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Price Performance
The business has a 50-day moving average price of C$0.02 and a 200 day moving average price of C$0.02. The company has a market cap of C$1.99 million, a price-to-earnings ratio of -0.75 and a beta of 0.37. The company has a current ratio of 0.12, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- MarketBeat Week in Review – 4/22 – 4/26
- What is a Death Cross in Stocks?
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Calculate Inflation Rate
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.